相关实验视频

Updated: Sep 20, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

泰戈普拉桑:一种新的,高度选择性的,强大的竞争性酸阻断剂 (P-CAB)

Wenlu Wang¹, Hafiza Sidra Yaseen², Xiaoji Li¹

¹Lijiang People's Hospital, Lijiang, China.

European journal of clinical pharmacology

|May 29, 2025

概括

泰戈普拉桑是一种新型的竞争性酸阻塞剂 (P-CAB),提供强效和持续的胃酸抑制,优于传统的质子抑制剂 (PPI). 它在治疗与酸有关的疾病方面表现有前途,具有有利的安全性.

科学领域:

药理学和治疗学药理学和治疗学
胃肠病学胃肠病学

背景情况:

质子抑制剂 (PPI) 在胃酸抑制方面存在局限性.
竞争性酸阻断剂 (P-CABs) 作为一种创新的药物类别,用于快速,强效和长时间的酸性抑制.
泰戈普拉赞是中国第一个自主开发的P-CAB.

研究的目的:

审查关于Tegoprazan药理学,药理动力学,药物相互作用,临床疗效和安全性的已发表文献.
评估Tegoprazan作为胃酸相关疾病的治疗方法.

主要方法:

进行了全面的文献搜索,截至2024年8月.
关于Tegoprazan的药理学,药理动力学,药理动力学,作用机制,药物相互作用,临床疗效和安全性概况的已发表文章的综述.

主要成果:

泰戈普拉桑通过抑制H+-K+-ATPase有效抑制胃酸.
它表现出比PPI更强大和更持久的酸性抑制,独立于食物摄入量和CYP2C19基因型.
临床试验显示,Tegoprazan (50-200毫克剂量) 对GERD,和H. pylori感染有显著的酸性抑制作用,可以控制胃肠道问题和头痛等不良事件.

结论:

泰戈普拉桑是一种耐受性良好且安全的新型P-CAB,用于胃酸疾病.
目前的研究主要局限于亚洲人群.
需要进一步的研究来探索Tegoprazan在不同种族群体中的影响.

关键词:

在H. Pylori的研究中,胃肠道疾病胃肠道疾病这就是P-CABs.个人隐私项目是个人隐私项目.安全的安全的安全的安全的安全.这就是Tegoprazan.

更多相关视频

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...